The INA Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population from human A-549 lung adenocarcinoma cells, featuring targeted INA gene disruption. This loss-of-function system enables the study of alpha-internexin’s non-neuronal roles, given its conventional association with neurofilament assembly and axonal integrity. The polyclonal nature provides a heterogeneous knockout pool, avoiding clonal isolation biases and delivering a robust platform for population-level analyses in cancer biology and cytoskeletal research.
The host A-549 cell line, originally derived from a 58-year-old Caucasian male lung adenocarcinoma, displays adherent epithelial morphology characteristic of alveolar type II cells. As a key model for lung epithelial biology, it recapitulates surfactant production, ion transport, and metabolic enzyme expression, supporting research in respiratory diseases, drug delivery, and oncogenesis. When used as the knockout host, this well-characterized epithelial background facilitates examination of how loss of a neuronal cytoskeletal protein alters cellular architecture and disease-relevant phenotypes such as migration and apoptosis.
INA encodes alpha-internexin, a type IV intermediate filament that co-assembles with neurofilament subunits NEFL, NEFM, and NEFH to form the neuronal cytoskeletal network critical for axon caliber and morphogenesis. Its regulation involves upstream factors NeuroD1, REST, and Notch signaling, while downstream it interacts with vimentin (VIM), CDK5, and GSK3?? to influence cytoskeletal organization and cellular mechanics. The network also interfaces with microtubule stability via tau (MAPT), placing INA at a convergence point for cytoskeletal integrity and signal transduction. In non-neuronal settings, these molecular interactions may redirect to support alternative filament scaffolds or epithelial-mesenchymal transition programs.
Disrupting INA in A-549 cells creates a model for probing non-canonical alpha-internexin functions beyond neurons. Neuroendocrine features, including neuronal cytoskeletal protein expression, occur in small cell lung cancer and neuroendocrine tumors, so this knockout can dissect INA’s role in transdifferentiation, plasticity, and metastasis. INA’s interactions with vimentin and CDK5 imply involvement in epithelial cytoskeletal remodeling, while Notch regulation connects it to lung cancer pathways. As a polyclonal population, it captures diverse editing events, enabling studies of gene dosage and compensatory network adaptations in a biologically relevant heterogeneous context.
Researchers can apply these polyclonal INA knockout cells in western blotting, immunofluorescence, and RT-qPCR for validation, and in functional assays for viability, apoptosis, migration, and invasion. Co-immunoprecipitation with confocal microscopy maps epithelial INA interactomes, while drug sensitivity tests assess modulation by Notch-targeted therapies. This model supports basic intermediate filament research and translational studies of neuroendocrine lung cancers. For technical details or experimental support, contact Ascent Research.
